Drug intelligence / Profile preview

BMS-986218 + degarelix

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

BMS-986218 + degarelix is a combination therapy under investigation for the treatment of prostate cancer, particularly in high-risk localized and advanced settings. Degarelix is a synthetic peptide that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist, rapidly suppressing testosterone production by blocking GnRH receptors in the pituitary gland. This leads to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately reducing testosterone levels and slowing prostate cancer growth[2][5][7]. BMS-986218 is an investigational non-fucosylated monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). It enhances immune-mediated anti-tumor activity by increasing Fcγ receptor binding, leading to improved regulatory T-cell depletion and enhanced antibody-dependent cellular cytotoxicity[6]. The combination aims to leverage androgen deprivation with immunotherapy to improve outcomes in prostate cancer patients[1][3][4].

Brand names: Firmagon
Other names: FE200486 (for degarelix)

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on BMS-986218 + degarelix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986218 + degarelix.

Explore the full profile